BioRestorative Therapies, Inc. 8-K

What Happened

• BioRestorative Therapies, Inc. (BRTX) filed an 8-K (May 29, 2026) disclosing two employment agreements and the results of a special stockholder meeting.
• On May 27, 2026 the company and CEO/Chair Lance Alstodt and CFO Robert E. Kristal each entered employment agreements running through May 27, 2029. Alstodt’s annual salary is $600,000 and Kristal’s is $350,000 (both unchanged from current levels).
• At a Special Meeting on May 26, 2026, stockholders approved an amendment increasing authorized common shares from 75,000,000 to 1,500,000,000.

Key Details

• Employment agreements dated May 27, 2026 with terms ending May 27, 2029.
• CEO Lance Alstodt: $600,000 annual salary; CFO Robert E. Kristal: $350,000 annual salary.
• Approved amendment increases authorized common stock from 75,000,000 to 1,500,000,000.
• Special Meeting vote tally on the amendment: For 9,868,606; Against 2,389,059; Abstentions 179,207.

Why It Matters

• The new employment agreements lock in senior leadership through 2029 and keep executive cash compensation unchanged, which may signal management continuity for investors.
• Expanding authorized shares gives the company legal capacity to issue many more shares (up to 1.5 billion), which can be used for future equity financings, acquisitions, or stock-based awards; such issuances would affect outstanding share count and potential dilution.
• Investors should watch for subsequent filings or announcements describing any planned share issuances or changes to executive compensation beyond base salaries.